Immatics NVNASDAQ:IMTX
- LAST PRICE13.0200
- TODAY'S CHANGE (%)0.0700 (0.5405%)
- Bid / Lots10.8800/ 2
- Ask / Lots16.0000/ 6
- Open / Previous Close12.8700 / 12.9500
- Day Range
- 52 Week Range
- Volume166,760
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMTX |
|---|---|---|
| 09:32 ET | 2855 | 12.87 |
| 09:38 ET | 1991 | 12.7 |
| 09:41 ET | 300 | 12.855 |
| 09:45 ET | 200 | 12.785 |
| 09:48 ET | 250 | 12.85 |
| 09:50 ET | 150 | 12.775 |
| 09:52 ET | 1090 | 12.77 |
| 09:54 ET | 300 | 12.745 |
| 09:57 ET | 4311 | 12.81 |
| 09:59 ET | 200 | 12.85 |
| 10:01 ET | 343 | 12.81 |
| 10:03 ET | 100 | 12.82 |
| 10:06 ET | 300 | 12.79 |
| 10:08 ET | 700 | 12.84 |
| 10:12 ET | 912 | 12.8 |
| 10:15 ET | 100 | 12.82 |
| 10:21 ET | 1310 | 12.85 |
| 10:24 ET | 350 | 12.89 |
| 10:26 ET | 685 | 12.82 |
| 10:28 ET | 250 | 12.84 |
| 10:44 ET | 1211 | 12.87 |
| 10:46 ET | 571 | 12.885 |
| 10:48 ET | 100 | 12.905 |
| 10:50 ET | 100 | 12.9 |
| 10:55 ET | 251 | 12.91 |
| 11:00 ET | 100 | 12.945 |
| 11:04 ET | 1100 | 12.95 |
| 11:06 ET | 1182 | 12.93 |
| 11:08 ET | 1467 | 12.865 |
| 11:11 ET | 400 | 12.84 |
| 11:18 ET | 200 | 12.855 |
| 11:20 ET | 111 | 12.9 |
| 11:29 ET | 400 | 12.89 |
| 11:31 ET | 200 | 12.915 |
| 11:38 ET | 250 | 12.89 |
| 11:40 ET | 100 | 12.885 |
| 11:42 ET | 164 | 12.87 |
| 11:49 ET | 1200 | 12.79 |
| 11:51 ET | 1000 | 12.81 |
| 11:54 ET | 172 | 12.87 |
| 11:56 ET | 100 | 12.85 |
| 12:00 ET | 200 | 12.83 |
| 12:14 ET | 600 | 12.865 |
| 12:18 ET | 964 | 12.865 |
| 12:20 ET | 300 | 12.865 |
| 12:21 ET | 300 | 12.93 |
| 12:23 ET | 100 | 12.915 |
| 12:27 ET | 361 | 12.88 |
| 12:38 ET | 200 | 12.865 |
| 12:39 ET | 400 | 12.89 |
| 12:41 ET | 400 | 12.89 |
| 12:43 ET | 200 | 12.86 |
| 12:45 ET | 2200 | 12.85 |
| 12:52 ET | 800 | 12.86 |
| 12:54 ET | 3541 | 12.9 |
| 12:56 ET | 346 | 12.89 |
| 12:59 ET | 300 | 12.87 |
| 01:03 ET | 100 | 12.89 |
| 01:12 ET | 200 | 12.94 |
| 01:19 ET | 700 | 12.96 |
| 01:21 ET | 582 | 12.95 |
| 01:24 ET | 100 | 12.96 |
| 01:26 ET | 454 | 12.92 |
| 01:35 ET | 470 | 12.94 |
| 01:39 ET | 590 | 12.942 |
| 01:44 ET | 275 | 12.92 |
| 01:48 ET | 300 | 12.97 |
| 01:51 ET | 100 | 12.965 |
| 01:55 ET | 201 | 12.96 |
| 01:57 ET | 310 | 12.96 |
| 02:00 ET | 3242 | 12.96 |
| 02:02 ET | 357 | 12.96 |
| 02:06 ET | 300 | 12.97 |
| 02:08 ET | 200 | 13.02 |
| 02:09 ET | 350 | 13.015 |
| 02:18 ET | 200 | 13.04 |
| 02:22 ET | 540 | 13.02 |
| 02:26 ET | 100 | 13.039 |
| 02:31 ET | 695 | 13.02 |
| 02:33 ET | 819 | 13 |
| 02:38 ET | 550 | 13.01 |
| 02:40 ET | 325 | 12.9999 |
| 02:42 ET | 100 | 12.99 |
| 02:44 ET | 200 | 12.98 |
| 02:45 ET | 521 | 12.98 |
| 02:47 ET | 200 | 12.95 |
| 02:58 ET | 300 | 12.96 |
| 03:02 ET | 300 | 12.95 |
| 03:05 ET | 100 | 12.96 |
| 03:09 ET | 1400 | 12.96 |
| 03:12 ET | 255 | 12.96 |
| 03:14 ET | 499 | 12.955 |
| 03:16 ET | 677 | 12.93 |
| 03:18 ET | 571 | 12.88 |
| 03:20 ET | 400 | 12.86 |
| 03:21 ET | 400 | 12.89 |
| 03:23 ET | 450 | 12.885 |
| 03:27 ET | 437 | 12.88 |
| 03:30 ET | 2014 | 12.91 |
| 03:32 ET | 749 | 12.92 |
| 03:34 ET | 250 | 12.92 |
| 03:36 ET | 800 | 12.94 |
| 03:38 ET | 200 | 12.94 |
| 03:39 ET | 914 | 12.96 |
| 03:41 ET | 600 | 12.99 |
| 03:43 ET | 414 | 12.99 |
| 03:45 ET | 900 | 13 |
| 03:48 ET | 3565 | 12.96 |
| 03:50 ET | 1002 | 13 |
| 03:52 ET | 908 | 12.99 |
| 03:54 ET | 819 | 12.99 |
| 03:56 ET | 4530 | 13.04 |
| 03:57 ET | 4341 | 13.04 |
| 03:59 ET | 36802 | 13.02 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Immatics NV | 1.3B | -12.5x | --- |
Vir Biotechnology Inc | 1.3B | -2.4x | --- |
Bicycle Therapeutics PLC | 1.6B | -5.2x | --- |
Arvinas Inc | 1.8B | -4.2x | --- |
Silence Therapeutics PLC | 900.5M | -16.7x | --- |
Soleno Therapeutics Inc | 1.5B | -15.8x | --- |
Company Information
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Contact Information
- Headquarters
- Paul Ehrlich-Strasse 15TUEBINGEN, Germany 72076
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Peter Chambre
- Chief Executive Officer, Executive Director
- Harpreet Singh
- Chief Financial Officer
- Arnd Christ
- Chief Operating Officer
- Steffen Walter
- General Counsel
- Edward Sturchio
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
|---|---|
Revenue (TTM) | $79.7M |
Shares Outstanding | 103.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.76 |
EPS | $-1.04 |
Book Value | $2.84 |
P/E Ratio | -12.5x |
Price/Sales (TTM) | 16.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -119.20% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
